Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer
Abstract Background To evaluate the clinicopathological and prognostic significance of the percentage change between maximum standardized uptake value (SUVmax) at 60 min (SUVmax1) and SUVmax at 120 min (SUVmax2) (ΔSUVmax%) using dual time point 18F-fluorodeoxyglucose emission tomography/computed tom...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-11-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-019-6315-8 |
| _version_ | 1819110158358282240 |
|---|---|
| author | Yoji YAMAGISHI Tomomi KOIWAI Tamio YAMASAKI Takahiro EINAMA Makiko FUKUMURA Miyuki HIRATSUKA Takako KONO Katsumi HAYASHI Jiro ISHIDA Hideki UENO Hitoshi TSUDA |
| author_facet | Yoji YAMAGISHI Tomomi KOIWAI Tamio YAMASAKI Takahiro EINAMA Makiko FUKUMURA Miyuki HIRATSUKA Takako KONO Katsumi HAYASHI Jiro ISHIDA Hideki UENO Hitoshi TSUDA |
| author_sort | Yoji YAMAGISHI |
| collection | DOAJ |
| description | Abstract Background To evaluate the clinicopathological and prognostic significance of the percentage change between maximum standardized uptake value (SUVmax) at 60 min (SUVmax1) and SUVmax at 120 min (SUVmax2) (ΔSUVmax%) using dual time point 18F-fluorodeoxyglucose emission tomography/computed tomography (18F-FDG PET/CT) in breast cancer. Methods Four hundred and sixty-four patients with primary breast cancer underwent 18F-FDG PET/CT for preoperative staging. ΔSUVmax% was defined as (SUVmax2 − SUVmax1) / SUVmax1 × 100. We explored the optimal cutoff value of SUVmax parameters (SUVmax1 and ΔSUVmax%) referring to the event of relapse by using receiver operator characteristic curves. The clinicopathological and prognostic significances of the SUVmax1 and ΔSUVmax% were analyzed by Cox’s univariate and multivariate analyses. Results The optimal cutoff values of SUVmax1 and ΔSUVmax% were 3.4 and 12.5, respectively. Relapse-free survival (RFS) curves were significantly different between high and low SUVmax1 groups (P = 0.0003) and also between high and low ΔSUVmax% groups (P = 0.0151). In Cox multivariate analysis for RFS, SUVmax1 was an independent prognostic factor (P = 0.0267) but ΔSUVmax% was not (P = 0.152). There was a weak correlation between SUVmax1 and ΔSUVmax% (P < 0.0001, R 2 = 0.166). On combining SUVmax1 and ΔSUVmax%, the subgroups of high SUVmax1 and high ΔSUVmax% showed significantly worse prognosis than the other groups in terms of RFS (P = 0.0002). Conclusion Dual time point 18F-FDG PET/CT evaluation can be a useful method for predicting relapse in patients with breast cancer. The combination of SUVmax1 and ΔSUVmax% was able to identify subgroups with worse prognosis more accurately than SUVmax1 alone. |
| first_indexed | 2024-12-22T03:37:16Z |
| format | Article |
| id | doaj.art-3dc70ae7d3024cca97f7f9c172a473b4 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-22T03:37:16Z |
| publishDate | 2019-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-3dc70ae7d3024cca97f7f9c172a473b42022-12-21T18:40:21ZengBMCBMC Cancer1471-24072019-11-0119111210.1186/s12885-019-6315-8Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancerYoji YAMAGISHI0Tomomi KOIWAI1Tamio YAMASAKI2Takahiro EINAMA3Makiko FUKUMURA4Miyuki HIRATSUKA5Takako KONO6Katsumi HAYASHI7Jiro ISHIDA8Hideki UENO9Hitoshi TSUDA10Department of Basic Pathology, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Basic Pathology, National Defense Medical CollegeDepartment of Radiology, National Defense Medical CollegeTokorozawa PET Diagnostic Imaging ClinicDepartment of Surgery, National Defense Medical CollegeDepartment of Basic Pathology, National Defense Medical CollegeAbstract Background To evaluate the clinicopathological and prognostic significance of the percentage change between maximum standardized uptake value (SUVmax) at 60 min (SUVmax1) and SUVmax at 120 min (SUVmax2) (ΔSUVmax%) using dual time point 18F-fluorodeoxyglucose emission tomography/computed tomography (18F-FDG PET/CT) in breast cancer. Methods Four hundred and sixty-four patients with primary breast cancer underwent 18F-FDG PET/CT for preoperative staging. ΔSUVmax% was defined as (SUVmax2 − SUVmax1) / SUVmax1 × 100. We explored the optimal cutoff value of SUVmax parameters (SUVmax1 and ΔSUVmax%) referring to the event of relapse by using receiver operator characteristic curves. The clinicopathological and prognostic significances of the SUVmax1 and ΔSUVmax% were analyzed by Cox’s univariate and multivariate analyses. Results The optimal cutoff values of SUVmax1 and ΔSUVmax% were 3.4 and 12.5, respectively. Relapse-free survival (RFS) curves were significantly different between high and low SUVmax1 groups (P = 0.0003) and also between high and low ΔSUVmax% groups (P = 0.0151). In Cox multivariate analysis for RFS, SUVmax1 was an independent prognostic factor (P = 0.0267) but ΔSUVmax% was not (P = 0.152). There was a weak correlation between SUVmax1 and ΔSUVmax% (P < 0.0001, R 2 = 0.166). On combining SUVmax1 and ΔSUVmax%, the subgroups of high SUVmax1 and high ΔSUVmax% showed significantly worse prognosis than the other groups in terms of RFS (P = 0.0002). Conclusion Dual time point 18F-FDG PET/CT evaluation can be a useful method for predicting relapse in patients with breast cancer. The combination of SUVmax1 and ΔSUVmax% was able to identify subgroups with worse prognosis more accurately than SUVmax1 alone.http://link.springer.com/article/10.1186/s12885-019-6315-8Dual time pointΔSUVmax%Primary breast cancer |
| spellingShingle | Yoji YAMAGISHI Tomomi KOIWAI Tamio YAMASAKI Takahiro EINAMA Makiko FUKUMURA Miyuki HIRATSUKA Takako KONO Katsumi HAYASHI Jiro ISHIDA Hideki UENO Hitoshi TSUDA Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer BMC Cancer Dual time point ΔSUVmax% Primary breast cancer |
| title | Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer |
| title_full | Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer |
| title_fullStr | Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer |
| title_full_unstemmed | Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer |
| title_short | Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer |
| title_sort | dual time point 18f fluorodeoxyglucose positron emission tomography computed tomography fusion imaging 18f fdg pet ct in primary breast cancer |
| topic | Dual time point ΔSUVmax% Primary breast cancer |
| url | http://link.springer.com/article/10.1186/s12885-019-6315-8 |
| work_keys_str_mv | AT yojiyamagishi dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT tomomikoiwai dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT tamioyamasaki dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT takahiroeinama dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT makikofukumura dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT miyukihiratsuka dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT takakokono dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT katsumihayashi dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT jiroishida dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT hidekiueno dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT hitoshitsuda dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer |